Harnessing the value of a network of specialists

The DPN brings together providers from across the community to support PACE. PACE will enable all aspects of outsourced project work (lab-based and consultancy) by connecting delivery partners with funded projects.

Absolute Antibody

Absolute Antibody was founded with a vision to make recombinant antibody technology accessible to all. We specialize in the sequencing, engineering, and recombinant production of antibodies. Our custom antibody engineering services include Fc silencing, humanization and chimerization, as well as the development of fragments, multispecific antibodies, and fusion proteins. We offer a unique catalog of recombinant antibodies, including clones to six bacteria listed in the World Health Organization’s priority pathogens report. All catalog clones are defined at the amino acid level to ensure batch-to-batch reproducibility and are available in different species, isotypes, and formats, with custom engineering available upon request.

ApconiX

ApconiX is an integrated toxicology consultancy and ion channel laboratory at the forefront of innovative thinking in nonclinical safety. With many years experience in the discovery and development of novel anti-infectives, ApconiX works with research teams to develop safer drugs by improving scientific and regulatory success.

ApconiX was founded in 2015 by Prof Ruth Roberts, Dr. Richard Knight and Dr. Mike Morton as a new approach to providing world-class nonclinical safety expertise to biotech, biopharma and academia.

BioAscent

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / MSD R&D site in Newhouse, Scotland, UK. Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening (including HTS), protein production, medicinal and synthetic chemistry, computational chemistry, and compound management, all with access to in-house diversity and fragment libraries. Our track record of success includes collaborations with academic groups to progress novel antibiotic drug discovery programs.

Boyds

Boyds is a consultancy providing services to support the development of new therapeutic products. We work with early-stage R&D companies, university spinouts and academic groups, and we are treatment modality and therapeutic area/clinical indication agnostic. We provide strategic/advisory and operational services including product development, regulatory affairs, clinical development, medical affairs, medical writing, QC, and publishing.

For PACE programme members, our Product Development team can provide integrated development planning and project management and oversight of external service providers (e.g., CDMOs, CROs), whilst our Regulatory team can undertake gap analyses, develop regulatory roadmaps, facilitate early regulatory agency interactions to help guide development. 

Charles River

Charles River is a highly respected, global provider of drug discovery and non-clinical development solutions, accelerating innovative research and development of drugs to support patients in need, including those exposed to antimicrobial-resistant infections. With a focus on clinical efficacy, we drive programs through a combination of multidisciplinary drug discovery expertise and capabilities in targets, translational platforms, therapeutic areas and across modalities. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.

Concept Life Sciences

We support your antimicrobial resistance (AMR) research through our expert services. We work across integrated drug discovery, from target validation to candidate selection, with expertise in medicinal chemistry and structural biology to design and refine molecules to effectively target resistant bacteria. 

We provide services in ADMET & DMPK in understanding how new antimicrobial agents behave in the body, biology and disease modelling, including assay development, screening, and disease modelling to study bacterial pathogens and identify molecules that can overcome resistance mechanisms, process research & API manufacturing, developing and optimising APIs, ensuring scalable and economically viable processes for early clinical trials. 

Work with us to advance your AMR research from Concept through to Clinic 

CPI

CPI is a leading independent technology innovation centre and founding member of the UK Government’s High Value Manufacturing Catapult. We connect academia, businesses, government, and investors to bring innovative ideas and research to the marketplace through our experts, equipment, networks, and funding. Our capabilities span AMR modalities including recombinant proteins, monoclonal antibodies, bacteriophage, anti-microbial and microbiome-related products, to translate your innovations into commercially viable processes. We help our customers develop solutions for infections resistant to conventional antibiotics, and through partnerships and advanced research, we strive to secure a healthier future by making a significant impact in the fight against AMR. 

Domainex

Domainex is a multi-award winning drug discovery service company that works collaboratively with clients from a variety of sectors (including pharmaceutical, biotechnology, academic and patient foundations) around the world. We have over 100 employees and our approach to drug discovery is truly integrated and collaborative. We offer the full range of pre-clinical drug discovery services supporting our clients at every stage of the journey, from disease target to candidate drug selection including protein production, assay development and screening, structural biology, medicinal, synthetic and analytical chemistry, hit-to-lead and lead optimisation. 

Evotec

At Evotec, infectious disease research is built on innovation and efficiency, driven by expert scientists. We leverage our extensive ID knowledge with Evotec’s advanced R&D platforms to address new antibacterial therapy challenges. Our sophisticated in vitro and in vivo capabilities, supported by a dedicated bioinformatics team and hollow fibre technology expertise, enable comprehensive support for infectious disease projects. Our experienced teams collaborate closely with yours, merging antibacterial expertise with Evotec’s platforms to deliver optimal solutions for antibacterial programs, ensuring smooth progress from research to clinical application. 

Pharmidex

Pharmidex is a UK-based CRO, founded in 2002, providing high quality, cost-effective and rapid solutions to clients in in vitro ADME, drug metabolism and pharmacokinetics (DMPK), bioanalysis (non-GLP, GLP/GCP), toxicology (non-GLP, GLP) and histology/clinical chemistry/ haematology.  Pharmidex also offers in silico modelling and efficacy models supporting oncology, CNS, respiratory, stroke, autoimmune and metabolic disease programmes.   

 Working with 250+ global clients, including medical charities, academic groups, biotech and pharma, undertaking 15000+ studies. In addition to our fee-for-service offering, Pharmidex is always seeking opportunities to collaborate in grant funded projects. We have successfully participated in 30+ collaborative grant funded projects to date.